Search Results - "Lotan, Tamara"

Clinical implications of PTEN loss in prostate cancer by Jamaspishvili, Tamara, Berman, David M., Ross, Ashley E., Scher, Howard I., De Marzo, Angelo M., Squire, Jeremy A., Lotan, Tamara L.

“…Key Points Large-scale next-generation genetic analyses of prostate cancer emphasize the frequent occurrence and importance of focal genomic deletions…”
Get full text

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer by Antonarakis, Emmanuel S, Lu, Changxue, Wang, Hao, Luber, Brandon, Nakazawa, Mary, Roeser, Jeffrey C, Chen, Yan, Mohammad, Tabrez A, Chen, Yidong, Fedor, Helen L, Lotan, Tamara L, Zheng, Qizhi, De Marzo, Angelo M, Isaacs, John T, Isaacs, William B, Nadal, Rosa, Paller, Channing J, Denmeade, Samuel R, Carducci, Michael A, Eisenberger, Mario A, Luo, Jun

“…Enzalutamide and abiraterone target the androgen receptor and androgen synthesis and are used to treat castration-resistant prostate cancer. A splice variant…”
Get full text

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations by Antonarakis, Emmanuel S., Shaukat, Farah, Isaacsson Velho, Pedro, Kaur, Harsimar, Shenderov, Eugene, Pardoll, Drew M., Lotan, Tamara L.

“…Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown. We conducted a…”
Get full text

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer by Akamatsu, Shusuke, Wyatt, Alexander W., Lin, Dong, Lysakowski, Summer, Zhang, Fan, Kim, Soojin, Tse, Charan, Wang, Kendric, Mo, Fan, Haegert, Anne, Brahmbhatt, Sonal, Bell, Robert, Adomat, Hans, Kawai, Yoshihisa, Xue, Hui, Dong, Xin, Fazli, Ladan, Tsai, Harrison, Lotan, Tamara L., Kossai, Myriam, Mosquera, Juan Miguel, Rubin, Mark A., Beltran, Himisha, Zoubeidi, Amina, Wang, Yuzhuo, Gleave, Martin E., Collins, Colin C.

“…More potent targeting of the androgen receptor (AR) in advanced prostate cancer is driving an increased incidence of neuroendocrine prostate cancer (NEPC), an…”
Get full text

De novo neuroendocrine features in prostate cancer by Abdulfatah, Eman, Fine, Samson W., Lotan, Tamara L., Mehra, Rohit

“…Neuroendocrine tumors of the prostate are rare and encompass a group of entities that are classified based on a combination of morphological and…”
Get full text

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial by Shenderov, Eugene, De Marzo, Angelo M., Lotan, Tamara L., Wang, Hao, Chan, Sin, Lim, Su Jin, Ji, Hongkai, Allaf, Mohamad E., Chapman, Carolyn, Moore, Paul A., Chen, Francine, Sorg, Kristina, White, Andrew M., Church, Sarah E., Hudson, Briana, Fields, Paul A., Hu, Shaohui, Denmeade, Samuel R., Pienta, Kenneth J., Pavlovich, Christian P., Ross, Ashley E., Drake, Charles G., Pardoll, Drew M., Antonarakis, Emmanuel S.

“…B7 homolog 3 (B7-H3; CD276 ), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with…”
Get full text

CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer by Lotan, Tamara L, Antonarakis, Emmanuel S

“…CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune…”
Get full text

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation by Epstein, Jonathan I, Amin, Mahul B, Beltran, Himisha, Lotan, Tamara L, Mosquera, Juan-Miguel, Reuter, Victor E, Robinson, Brian D, Troncoso, Patricia, Rubin, Mark A

“…On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine (NE)…”
Get full text

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited by Deek, Matthew P., Van der Eecken, Kim, Phillips, Ryan, Parikh, Neil R., Isaacsson Velho, Pedro, Lotan, Tamara L., Kishan, Amar U., Maurer, Tobias, Boutros, Paul C., Hovens, Christopher, Abramowtiz, Matthew, Pollack, Alan, Desai, Neil, Stish, Bradley, Feng, Felix Y., Eisenberger, Mario, Carducci, Michael, Pienta, Kenneth J., Markowski, Mark, Paller, Channing J., Antonarakis, Emmanuel S., Berlin, Alejandro, Ost, Piet, Tran, Phuoc T.

“…Emerging data suggest that metastasis is a spectrum of disease burden rather than a binary state, and local therapies, such as radiation, might improve…”
Get full text

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer by Lotan, Tamara L., Kaur, Harsimar B., Salles, Daniela C., Murali, Sanjana, Schaeffer, Edward M., Lanchbury, Jerry S., Isaacs, William B., Brown, Robert, Richardson, Andrea L., Cussenot, Olivier, Cancel-Tassin, Geraldine, Timms, Kirsten M., Antonarakis, Emmanuel S.

“…The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer…”
Get full text

Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma by TAN, Hsueh-Li, AKSHAY SOOD, WENNUAN LIU, ISAACS, William B, DE MARZO, Angelo M, LOTAN, Tamara L, RAHIMI, Hameed A, WENLE WANG, GUPTA, Nilesh, HICKS, Jessica, MOSIER, Stacy, GOCKE, Christopher D, EPSTEIN, Jonathan I, NETTO, George J

“…Small cell neuroendocrine carcinoma of the prostate is likely to become increasingly common with recent advances in pharmacologic androgen suppression. Thus,…”
Get full text

Reprint of: de novo neuroendocrine features in prostate cancer by Abdulfatah, Eman, Fine, Samson W., Lotan, Tamara L., Mehra, Rohit

“…Neuroendocrine tumors of the prostate are rare and encompass a group of entities that are classified based on a combination of morphological and…”
Get full text

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer by Isaacsson Velho, Pedro, Silberstein, John L., Markowski, Mark C., Luo, Jun, Lotan, Tamara L., Isaacs, William B., Antonarakis, Emmanuel S.

“…Background Germline mutations in genes mediating DNA repair are common in men with recurrent and advanced prostate cancer, and their presence may alter…”
Get full text

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials by Deek, Matthew P, Van der Eecken, Kim, Sutera, Philip, Deek, Rebecca A, Fonteyne, Valérie, Mendes, Adrianna A, Decaestecker, Karel, Kiess, Ana Ponce, Lumen, Nicolaas, Phillips, Ryan, De Bruycker, Aurélie, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Lambert, Bieke, Delrue, Louke, Wang, Hailun, Lowe, Kathryn, Verbeke, Sofie, Van Dorpe, Jo, Bultijnck, Renée, Villeirs, Geert, De Man, Kathia, Ameye, Filip, Song, Daniel Y, DeWeese, Theodore, Paller, Channing J, Feng, Felix Y, Wyatt, Alexander, Pienta, Kenneth J, Diehn, Maximillian, Bentzen, Soren M, Joniau, Steven, Vanhaverbeke, Friedl, De Meerleer, Gert, Antonarakis, Emmanuel S, Lotan, Tamara L, Berlin, Alejandro, Siva, Shankar, Ost, Piet, Tran, Phuoc T

“…JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer…”
Get full text

Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others by Li, Huili, Argani, Pedram, Halper-Stromberg, Eitan, Lotan, Tamara L, Merino, Maria J, Reuter, Victor E, Matoso, Andres

“…Renal cell carcinoma with fibromyomatous stroma (RCCFMS) include ELOC/TCEB1 -mutated renal cell carcinoma (RCC) and those with TSC1/2 / MTOR alterations…”
Get full text

MSH2 Loss in Primary Prostate Cancer by Guedes, Liana B, Antonarakis, Emmanuel S, Schweizer, Michael T, Mirkheshti, Nooshin, Almutairi, Fawaz, Park, Jong Chul, Glavaris, Stephanie, Hicks, Jessica, Eisenberger, Mario A, De Marzo, Angelo M, Epstein, Jonathan I, Isaacs, William B, Eshleman, James R, Pritchard, Colin C, Lotan, Tamara L

“…Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with…”
Get full text

GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasms by Salles, Daniela C, Asrani, Kaushal, Woo, Juhyung, Vidotto, Thiago, Liu, Hans B, Vidal, Igor, Matoso, Andres, Netto, George J, Argani, Pedram, Lotan, Tamara L

“…GPNMB (glycoprotein nonmetastatic B) and other TFE3/TFEB transcriptional targets have been proposed as markers for microphthalmia (MiT) translocation renal…”
Get full text

Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes by Weiner, Adam B., Vidotto, Thiago, Liu, Yang, Mendes, Adrianna A., Salles, Daniela C., Faisal, Farzana A., Murali, Sanjana, McFarlane, Matthew, Imada, Eddie L., Zhao, Xin, Li, Ziwen, Davicioni, Elai, Marchionni, Luigi, Chinnaiyan, Arul M., Freedland, Stephen J., Spratt, Daniel E., Wu, Jennifer D., Lotan, Tamara L., Schaeffer, Edward M.

“…Black men die more often of prostate cancer yet, interestingly, may derive greater survival benefits from immune-based treatment with sipuleucel-T. Since no…”
Get full text

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma by Tsai, Harrison K, Lehrer, Jonathan, Alshalalfa, Mohammed, Erho, Nicholas, Davicioni, Elai, Lotan, Tamara L

“…Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary…”
Get full text

A PRC2-independent function for EZH2 in regulating rRNA 2′-O methylation and IRES-dependent translation by Yi, Yang, Li, Yanqiang, Meng, Qingshu, Li, Qiaqia, Li, Fuxi, Lu, Bing, Shen, Jiangchuan, Fazli, Ladan, Zhao, Dongyu, Li, Chao, Jiang, Weihua, Wang, Rui, Liu, Qipeng, Szczepanski, Aileen, Li, Qianru, Qin, Wei, Weiner, Adam B., Lotan, Tamara L., Ji, Zhe, Kalantry, Sundeep, Wang, Lu, Schaeffer, Edward M., Niu, Hengyao, Dong, Xuesen, Zhao, Wei, Chen, Kaifu, Cao, Qi

“…Dysregulated translation is a common feature of cancer. Uncovering its governing factors and underlying mechanism are important for cancer therapy. Here, we…”
Get full text